SER

Serina is a clinical-stage biotech whose entire value rests on an unproven POZ (poly(2-oxazoline)) drug-delivery platform, with lead candidate SER-252 only now advancing into Phase I. The 'revenue' line is a rounding error — $130K in FY2025 against a $19.2M net loss and a $24.0M operating loss — so the 180x P/S is meaningless; this is a cash-burn story, not a business. Management itself states there is 'substantial doubt about our ability to continue as a going concern,' the single most important fact in the filing.

The balance sheet is broken. Cash fell to $3.06M against operating cash burn of $18.0M per year — roughly two months of runway — while stockholders' equity has gone negative (-$37K) and liabilities/equity is meaningless at -188.86x. The accumulated deficit is $63.5M and R&D spend rose 76% to $13.2M, so burn is accelerating, not stabilizing. The company explicitly says it 'will require additional financing' and expects expenses to 'increase significantly.' With only 12.3M shares and an active ATM plus a Juvenescence warrant overhang, the near-certain capital raise at $1.90 is deeply dilutive; share count already grew 24% in a year.